Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient

82Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a case of a 24-year-old liver transplant recipient who developed hepatic artery thrombosis and graft failure, which was complicated by subphrenic abscess and persistent Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae bacteremia. Ceftazidime-avibactam treatment led to emergence of resistance, and alternative combination therapy failed due to persistent infection and toxicity. The infection resolved after initiation of meropenem-vaborbactam, which created a bridge to retransplantation. Treatment-emergent ceftazidime-avibactam resistance is increasingly recognized, suggesting a role for meropenem-vaborbactam.

Cite

CITATION STYLE

APA

Athans, V., Neuner, E. A., Hassouna, H., Richter, S. S., Keller, G., Castanheira, M., … Mathers, A. J. (2019). Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrobial Agents and Chemotherapy, 63(1). https://doi.org/10.1128/AAC.01551-18

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free